| Today’s Big NewsMar 3, 2025 |
| By Nick Paul Taylor AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the drugmaker rights to a long-acting amylin analog that is in phase 1 development at Gubra. |
|
|
|
By James Waldron Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug reduced blood procedures among patients with a rare type of cancer in a phase 3 trial. |
By Gabrielle Masson After a rocky two years, money has started flowing back to biotech, with the return of the megaround exemplified in top moneymaker Xaira’s $1 billion fundraise. |
By James Waldron Oqory’s planned reverse merger with fellow antibody-drug conjugate company Vincerx Pharma has fallen apart at the last minute, leaving Vincerx to size up its remaining options in the final months before its cash runs dry. |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT In the world of clinical trials, where precision and compliance are critical, the role of technology is more important than ever. Join us to learn how to harness the latest innovations for driving efficiencies and more streamlined experiences for patients. Register now to take a deep dive into the most pressing challenges in clinical trials today!
|
|
By James Waldron Neumora halted one trial of its depression drug navacaprant and paused another pair of late-stage studies as it tries to learn from a recent phase 3 failure. |
By Zoey Becker The company is handing back the tumor candidate it snapped up in 2021 after initiating a phase 2 trial of the anti-ITL2 monoclonal antibody. |
By James Waldron Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload antibody-drug conjugate that’s ready for the clinic. |
By Darren Incorvaia With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster debut of its own. The British Big Pharma has filed depemokimab for FDA approval in two respiratory indications on the back of new phase 3 data showing the antibody improved disease symptoms and quality of life in patients with chronic rhinosinusitis with nasal polyps. |
By Nick Paul Taylor Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. The biotech focused on low-dose results from its latest phase 2 trial, rather than the overall primary endpoint miss, but investors took a much more downbeat view of the data. |
By Nick Paul Taylor Novo Nordisk has forged a deal with Gensaic, agreeing to pay up to $354 million per target to access technology for the tissue-selective delivery of molecules to cardiometabolic targets inside cells. |
By Angus Liu A new policy from President Donald Trump aims to restrict both inbound and outbound investments related to China in certain strategic industries, including biotechnology. |
By Heather Landi Public health experts are sounding the alarm about the outbreak and warn that communities with low immunization rates are at greatest risk for further spread of the disease. |
By Andrea Park Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. |
By Heather Landi,Fierce Healthcare Staff Meet the winners of Fierce Healthcare's Fierce 15 of 2025. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we hear from Steven McCarroll, Ph.D., whose research team at the Broad Institute of MIT and Harvard recently uncovered new insights into the cause of Huntington's disease. |
|
|---|
|
|
|
Thursday, March 20, 2025 | 11am ET / 8am PT AI is no longer a novelty—it's an expectation. As stakeholders demand evidence of real-world impact, the focus is shifting from the tools themselves to the tangible results they deliver. Join us to explore how predictive sales intelligence and omnichannel strategies are transforming HCP engagement. Register now.
|
|
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
